CRINETICS PHARMACEUTICALS IN (CRNX) Stock Analyst Earnings Estimates
NASDAQ:CRNX - Nasdaq - US22663K1079 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.08M 1,442.86% | 4.74M 338.89% | 4.013M -15.34% | 1.648M -58.93% | 4.865M 195.21% | 40.342M 729.23% | 213.74M 429.82% | 529.41M 147.69% | 1.206B 127.80% | 1.998B 65.67% | 1.989B -0.45% | 2.111B 6.13% | |
| EBITDA YoY % growth | -106.78M -44.30% | -166.9M -56.30% | -221.51M -32.72% | -340.172M -53.57% | -416.881M -22.55% | -443.8M -6.46% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -107.7M -43.70% | -167.88M -55.88% | -222.608M -32.60% | -336.64M -51.23% | -403.426M -19.84% | -456.034M -13.04% | -320.575M 29.70% | -74.183M 76.86% | 496.07M 768.71% | 1.14B 129.81% | 1.408B 23.51% | 1.815B 28.91% | |
| Operating Margin | -9,972.22% | -3,541.77% | -5,547.17% | -20,427.16% | -8,292.41% | -1,130.42% | -149.98% | -14.01% | 41.13% | 57.06% | 70.79% | 85.98% | |
| EPS YoY % growth | -2.80 -13.82% | -3.14 -12.14% | -3.70 -17.83% | -3.78 -2.27% | -3.96 -4.56% | -4.63 -17.06% | -3.21 30.68% | -0.52 83.88% | 4.64 997.20% | 8.90 91.73% | 9.23 3.61% | 11.01 19.29% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.91 -0.82% | -0.96 -3.57% | -1.03 -9.44% | -1.11 -16.12% | -1.15 -26.38% | -1.07 -11.19% | -1.10 -7.08% | -1.13 -1.11% | -1.15 -0.51% |
| Revenue Q2Q % growth | 765K | 14.576K -97.72% | 39.097K -90.20% | 438.6K | 3.784M 394.64% | 5.605M 38,354.15% | 7.339M 18,671.45% | 10.338M 2,257.05% | 14.275M 277.25% |
| EBITDA Q2Q % growth | -88.132M -43.16% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -87.523M -39.68% | -90.886M -23.61% | -96.915M -17.07% | -103.788M -18.21% | -106.91M -22.15% | -99.615M -9.60% | -102.512M -5.78% | -104.497M -0.68% | -105.282M 1.52% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.96 4.95% | -0.93 | -0.03 | -3.35% |
| Q2 2024 Q2Q % growth | -0.94 | -0.88 | -0.06 | -7.29% |
| Q1 2024 Q2Q % growth | -0.93 -9.41% | -0.83 | -0.10 | -12.64% |
| Q4 2023 Q2Q % growth | -0.90 -7.14% | -0.88 | -0.02 | -2.31% |
| Q3 2023 Q2Q % growth | -1.01 -29.49% | -0.88 | -0.13 | -15.29% |
| Q2 2023 Q2Q % growth | -0.94 -16.05% | -0.87 | -0.07 | -7.46% |
| Q1 2023 Q2Q % growth | -0.85 -19.72% | -0.83 | -0.02 | -2.64% |
| Q4 2022 Q2Q % growth | -0.84 -23.53% | -0.84 | 0.00 | -0.23% |
| Q3 2022 Q2Q % growth | -0.78 -6.85% | -0.85 | 0.07 | 8.05% |
| Q2 2022 Q2Q % growth | -0.81 -15.71% | -0.69 | -0.12 | -17.94% |
| Q1 2022 Q2Q % growth | -0.71 -2.90% | -0.59 | -0.12 | -20.01% |
| Q4 2021 Q2Q % growth | -0.68 -3.03% | -0.64 | -0.04 | -6.67% |
| Q3 2021 Q2Q % growth | -0.73 -30.36% | -0.73 | 0.00 | 0.04% |
| Q2 2021 Q2Q % growth | -0.70 -32.08% | -0.62 | -0.08 | -12.50% |
| Q1 2021 Q2Q % growth | -0.69 2.82% | -0.67 | -0.02 | -2.50% |
| Q4 2020 Q2Q % growth | -0.66 -10.00% | -0.59 | -0.07 | -11.95% |
| Q3 2020 Q2Q % growth | -0.56 6.67% | -0.54 | -0.02 | -4.38% |
| Q2 2020 Q2Q % growth | -0.53 -3.92% | -0.58 | 0.05 | 8.20% |
| Q1 2020 Q2Q % growth | -0.71 -91.89% | -0.64 | -0.07 | -10.49% |
| Q4 2019 Q2Q % growth | -0.60 | -0.69 | 0.09 | 13.07% |
| Q3 2019 Q2Q % growth | -0.60 | -0.58 | -0.02 | -3.56% |
| Q2 2019 Q2Q % growth | -0.51 | -0.47 | -0.04 | -9.65% |
| Q1 2019 Q2Q % growth | -0.37 | -0.42 | 0.05 | 11.53% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -100.00% | 244.8K | -244.8K | -100.00% |
| Q2 2024 Q2Q % growth | 399K -59.62% | 520.2K | -121.2K | -23.30% |
| Q1 2024 Q2Q % growth | 640K -76.11% | 260.671K | 379.329K | 145.52% |
| Q4 2023 Q2Q % growth | -100.00% | 265.2K | -265.2K | -100.00% |
| Q3 2023 Q2Q % growth | 346K -24.78% | 125.97K | 220.03K | 174.67% |
| Q2 2023 Q2Q % growth | 988K 124.55% | 574.433K | 413.567K | 72.00% |
| Q1 2023 Q2Q % growth | 2.679M -14.41% | 351.023K | 2.328M | 663.20% |
| Q4 2022 Q2Q % growth | 710K -34.26% | 255K | 455K | 178.43% |
| Q3 2022 Q2Q % growth | 460K | 170.003K | 289.997K | 170.58% |
| Q2 2022 Q2Q % growth | 440K | 612K | -172K | -28.10% |
| Q1 2022 Q2Q % growth | 3.13M | 5.304M | -2.174M | -40.99% |
| Q1 2021 Q2Q % growth | -100.00% | % | ||
| Q4 2020 Q2Q % growth | -100.00% | % | ||
| Q3 2020 Q2Q % growth | -100.00% | % | ||
| Q1 2020 Q2Q % growth | 70K -81.08% | 70K | % | |
| Q4 2019 Q2Q % growth | 320K | 110.497K | 209.503K | 189.60% |
| Q3 2019 Q2Q % growth | 510K | 153K | 357K | 233.33% |
| Q2 2019 Q2Q % growth | 153K | -153K | -100.00% | |
| Q1 2019 Q2Q % growth | 370K | 132.6K | 237.4K | 179.03% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | -0.34% | 0% | -0.31% |
| Revenue | 0% | 2.27% | 0% | -17.48% |